Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 5:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: CEA Clear all
Completed Not applicable Interventional

Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial

NCT02089217
View directory record Official record
Conditions
Carotid Stenosis
Interventions
Carotid endarterectomy (CEA), Carotid Stenting (CAS), Intensive Medical Management - no CEA, Intensive Medical Management - no CAS
Procedure · Device · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 100 Years
Enrollment
2,486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
154
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 112 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 13, 2026, 5:49 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

NCT03387085
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Aldoxorubicin HCl, N-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK for Infusion, avelumab, bevacizumab, Capecitabine, Cisplatin, Cyclophosphamide, 5-Fluorouracil, Leucovorin, nab-Paclitaxel, SBRT
Drug · Biological · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 13, 2026, 5:49 AM EDT
Completed No phase listed Observational

Accuracy of Dilution of EUS-FNA Pancreatic Cyst Fluid for Carcinoembryonic Antigen (CEA) Measurement

NCT01494077
View directory record Official record
Conditions
Pancreatic Cyst
Interventions
Laboratory processing for results
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Sep 13, 2026, 5:49 AM EDT
Recruiting Phase 1 Interventional

Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer

NCT06130826
View directory record Official record
Conditions
Breast Carcinoma, Colorectal Carcinoma
Interventions
Biopsy, Biospecimen Collection, Bone Scan, Computed Tomography, Immunotherapy, Magnetic Resonance Imaging, Positron Emission Tomography, Stereotactic Body Radiation Therapy
Procedure · Drug · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 13, 2026, 5:49 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Trial Comparison of Accuseal and Bovine Pericardial Patch During Endarterectomy

NCT01184183
View directory record Official record
Conditions
Coronary Stenosis
Interventions
Comparing Accuseal Vs. Bovine Pericardial in CEA
Procedure
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 13, 2026, 5:49 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT-3.080: NANT Pancreatic Cancer Vaccine

NCT03586869
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Aldoxorubicin HCl, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK for infusion, bevacizumab, Capecitabine, Cyclophosphamide, Fluorouracil, Leucovorin, nab-Paclitaxel, Oxaliplatin, Avelumab, SBRT
Drug · Biological · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Phase 1 Interventional

A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors

NCT02350673
View directory record Official record
Conditions
Solid Tumors
Interventions
Atezolizumab, Cergutuzumab Amunaleukin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
4
States / cities
New Haven, Connecticut • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 13, 2026, 5:49 AM EDT
Recruiting No phase listed Observational

Stage II/III Colorectal Cancer Recurrence

NCT06314958
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Stage II, Colorectal Cancer Stage III, Colorectal Cancer Recurrent
Interventions
CENSURE
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Monrovia, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 13, 2026, 5:49 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Panc CA Risk Model & Biomarker Testing In High-Risk Cohort

NCT05287347
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Blood Specimen
Diagnostic Test
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Phase 1 Interventional

CEA-Expressing Liver Metastases Safety Study of Intrahepatic Infusions of Anti-CEA Designer T Cells

NCT01373047
View directory record Official record
Conditions
Liver Metastases
Interventions
anti-CEA 2nd generation designer T cells
Biological
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Not applicable Interventional Results available

Compare Preperitoneal Analgesia to Epidural Analgesia for Pain Control After Colon and Rectal Surgery

NCT01552226
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer, Colonic Diverticulosis
Interventions
Continuous Preperitoneal Analgesia, Continuous Epidural Analgesia
Device
Lead sponsor
Trinity Health Michigan
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

QUILT-3.006 for Recurrent Medullary Thyroid Cancer

NCT01856920
View directory record Official record
Conditions
Medullary Thyroid Cancer (MTC)
Interventions
GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]
Biological
Lead sponsor
NantCell, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Phase 4 Interventional Results available

A Carotid Stenting Boston Scientific Surveillance Program

NCT00741091
View directory record Official record
Conditions
Carotid Artery Disease
Interventions
Carotid WALLSTENT Monorail Endoprosthesis, FilterWire EZ™ System™
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,097 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
112
States / cities
Birmingham, Alabama • Fairhope, Alabama • Phoenix, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2011 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Phase 1 Interventional

An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ...

NCT00924092
View directory record Official record
Conditions
Prostate Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Head and Neck Cancer
Interventions
GI-6207 [Recombinant Saccharomyces Cerevisia, (Yeast CEA Vaccine)(GI-6207[Recombinant Sarrcharomyces Cerevusua-CEA (610D)])
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Phase 1Phase 2 Interventional

Radioimmunotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer

NCT00004085
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, yttrium Y 90 monoclonal antibody MN-14
Biological · Procedure · Radiation
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
3
States / cities
Belleville, New Jersey • Paterson, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Sep 13, 2026, 5:49 AM EDT
Recruiting Not applicable Interventional

Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL) System for the Treatment of Calcified Carotid Arteries Prior to Trans-Carotid Stenting (SKYWARD Trans-Carotid IDE [Investigational Device Exemption] Study)

NCT07062471
View directory record Official record
Conditions
Carotid Artery Calcification, Carotid Artery Diseases
Interventions
Carotid Intravascular Lithotripsy (IVL)
Device
Lead sponsor
Shockwave Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
25
States / cities
Little Rock, Arkansas • Rancho Mirage, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Not applicable Interventional Results available

Carotid Revascularization Endarterectomy Versus Stenting Trial

NCT00004732
View directory record Official record
Conditions
Atherosclerosis, Stroke, Carotid Stenosis, Cerebral Infarction, Myocardial Infarction
Interventions
Carotid Endarterectomy (CEA), Carotid Artery Stenting (CAS)
Procedure · Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
2,502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2016
U.S. locations
106
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Sep 13, 2026, 5:49 AM EDT
Active, not recruiting Phase 2 Interventional

Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome

NCT05419011
View directory record Official record
Conditions
Colorectal Carcinoma, Colorectal Neoplasm, Lynch Syndrome
Interventions
Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5, Biopsy Procedure, Biospecimen Collection, Colonoscopy, Nogapendekin Alfa, Placebo Administration, Questionnaire Administration
Biological · Procedure · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
13
States / cities
Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 13, 2026, 5:49 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

NCT03387111
View directory record Official record
Conditions
Squamous Cell Carcinoma
Interventions
Aldoxorubicin HCl, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK for infusion, Avelumab, bevacizumab, Capecitabine, Cetuximab, Cisplatin, Cyclophosphamide, Fluorouracil, Leucovorin, nab-Paclitaxel, Necitumumab, SBRT, N-803
Drug · Biological · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2024 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma

NCT00203892
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
modified CEA peptide (10mcg), modified CEA peptide (100mcg), modified CEA peptide (1000mcg)
Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Sep 13, 2026, 5:49 AM EDT
Suspended Phase 2 Interventional

Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas

NCT01723306
View directory record Official record
Conditions
Metastatic Cancers
Interventions
Gene Modified T Cells
Genetic
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Phase 1 Interventional

Biological Therapy in Treating Patients With Metastatic Cancer

NCT00004604
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Metastatic Cancer, Ovarian Cancer, Pancreatic Cancer, Testicular Germ Cell Tumor
Interventions
CEA RNA-pulsed DC cancer vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Sep 13, 2026, 5:49 AM EDT
Active, not recruiting Early Phase 1 Interventional

An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer

NCT05245786
View directory record Official record
Conditions
Locally Advanced Rectal Carcinoma, Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8
Interventions
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A, Imaging Technique
Biological · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 13, 2026, 5:49 AM EDT
Terminated Phase 2 Interventional Results available

Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA

NCT05245071
View directory record Official record
Conditions
Non-squamous Non-small Cell Lung Cancer
Interventions
Tusamitamab ravtansine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Buffalo, New York • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Sep 13, 2026, 5:49 AM EDT